Zydus Pharmaceuticals

Published Online: Tuesday, July 23, 2013
Follow Pharmacy_Times:

Zydus Pharmaceuticals (USA) Inc, located in Pennington, New Jersey, is looking forward to its future in the US pharmaceutical market. Since its first commercial launch in August 2005, it has grown steadily over the past 7 years and now offers more than 260 SKUs to the US market. For the seventh straight year, IMS Health has recognized Zydus as one of the fastest growing pharmaceutical companies by total prescriptions dispensed. IMS Health also listed Zydus in the top 10 (ranked number 10) US generic companies based on total prescriptions dispensed.

This is an exciting time for Zydus as the company continues to expand its portfolio to offer new dosage forms and enter different franchises within the US pharmaceutical market. With the purchase of Nesher Pharmaceuticals in St. Louis, Missouri, Zydus has a footprint in the US that has allowed the company to enter the controlled substances sector. Zydus has also launched its first injectable product (Ranitidine HCl injection) this past year. In the near future, Zydus hopes to introduce nasal sprays for the first time in the US. Zydus is also aggressively pursuing other franchises, such as dermatologic and oncology products, as well as metered dose inhalers. The company has worked extremely hard to put together a rich product pipeline for the future.

Zydus Pharmaceuticals’ parent company, Zydus Cadila, is India’s fifth-largest pharmaceutical company and has experienced tremendous growth over the past several years. It is a global pharmaceutical company with business operations in more than 50 countries, including the United States, European countries, Japan, Spain, Brazil, and Mexico. With more than 14,000 employees across 26 countries, India’s largest finished dosage plant under 1 roof, 2 FDA-approved API sites, and the ability to manufacture a wide variety of dosage forms, Zydus Cadila is more than ready to support the rapidly growing US pharmaceutical market. With the FDA approval of its Baddi plant and its newest manufacturing plant completed, Zydus will soon have a pill and capsule capacity exceeding 20 billion annually.

With the strength and worldwide reputation of Zydus Cadila supporting the US division, Zydus Pharmaceuticals is looking forward to continuing its growth in the US marketplace. As the company focuses its efforts on more challenging and rewarding opportunities, including several first-to-file and 505B2 opportunities, it looks forward to great success as the company expands. To date, Zydus has filed 112 drug master files (DMFs), received 74 Abbreviated New Drug Application (ANDA) final and tentative approvals, and has 84 ANDAs pending approval with the FDA. Look for some exciting announcements from Zydus over the next 12 months, as it is truly “poised for the future.”

You can visit Zydus Pharmaceuticals (USA) Inc. at NACDS Pharmacy and Technology at booth 2808 or learn more about the company through its website at www.zydususa.com.

Related Articles
The FDA is seeking comments on 28 new and 15 revised recommendations providing product-specific guidance on the design of bioequivalence studies to support Abbreviated New Drug Applications (ANDAs).
Community pharmacists are most concerned about below-cost reimbursement for certain generic drugs as well as exclusionary Medicare drug plans according to a survey conducted by the National Community Pharmacists Association that asked its members to help identify the organization’s 2015 priorities.
A bill to make pharmacy benefit managers’ reimbursements for generic drugs more transparent will cover more federal health care programs than a bill introduced earlier this year.
Today Reps. Doug Collins (R-Ga.) and Dave Loebsack (D-Iowa) introduced H.R. 5815, The Generic Drug Pricing Fairness Act, which creates greater transparency in how pharmacy benefit managers reimburse pharmacies for generic prescription drugs under Medicare Part D, and the Federal Employees Health Benefits Program. The National Community Pharmacists Association endorsed the bill, which goes further than legislation the same two Congressmen introduced earlier year that has the same remedies, but only applied to Medicare Part D.
Latest Issues
  • photo
    Pharmacy Times
    Health-System Edition
    Directions in Pharmacy
    OTC Guide
    Generic Supplements
  • photo
    Pharmacy Careers
    Specialty Pharmacy Times